{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vlad RA"],"funding":["University of Medicine, Pharmacy, Science and, Technology George Emil Palade of Târgu Mureș"],"pagination":["1467"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9324952"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(7)"],"pubmed_abstract":["Orodispersible tablets (ODTs) are pharmaceutical formulations used to obtain fast therapeutic effects, usually recommended for geriatric and pediatric patients due to their improved compliance, bioavailability, ease of administration, and good palatability. This study aimed to develop ODTs with cannabidiol (CBD) phytocannabinoid extracted from <i>Cannabis sativa</i> used in the treatment of Lennox-Gastaut and Dravet syndromes. The tablets were obtained using an eccentric tableting machine and 9 mm punches. To develop CBD ODTs, the following parameters were varied: the Poloxamer 407 concentration (0 and 10%), the type of co-processed excipient (Prosolv<sup>®</sup> ODT G2-PODTG2 and Prosolv<sup>®</sup> EasyTab sp-PETsp), and the type of superdisintegrant (Croscarmellose-CCS, and Soy Polysacc"],"journal":["Pharmaceutics"],"pubmed_title":["Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 2<sup>3</sup>-Factorial Design."],"pmcid":["PMC9324952"],"funding_grant_id":["10127/17.12.2020"],"pubmed_authors":["Muntean DL","Todoran N","Farczadi L","Birsan M","Antonoaea P","Ciurba A","Imre S","Hancu G","Vlad RA","Redai EM"],"additional_accession":[]},"is_claimable":false,"name":"Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 2<sup>3</sup>-Factorial Design.","description":"Orodispersible tablets (ODTs) are pharmaceutical formulations used to obtain fast therapeutic effects, usually recommended for geriatric and pediatric patients due to their improved compliance, bioavailability, ease of administration, and good palatability. This study aimed to develop ODTs with cannabidiol (CBD) phytocannabinoid extracted from <i>Cannabis sativa</i> used in the treatment of Lennox-Gastaut and Dravet syndromes. The tablets were obtained using an eccentric tableting machine and 9 mm punches. To develop CBD ODTs, the following parameters were varied: the Poloxamer 407 concentration (0 and 10%), the type of co-processed excipient (Prosolv<sup>®</sup> ODT G2-PODTG2 and Prosolv<sup>®</sup> EasyTab sp-PETsp), and the type of superdisintegrant (Croscarmellose-CCS, and Soy Polysacc","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-05T16:13:30.488Z","creation":"2022-08-07T06:28:37.384Z"},"accession":"S-EPMC9324952","cross_references":{"pubmed":["35890362"],"doi":["10.3390/pharmaceutics14071467"]}}